These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 21860121)

  • 1. Newer β-lactam and β-lactamase inhibitor combinations available in India: consensus and controversies.
    Veeraraghavan B
    Indian J Med Microbiol; 2011; 29(3):315-6. PubMed ID: 21860121
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update.
    Shahid M; Sobia F; Singh A; Malik A; Khan HM; Jonas D; Hawkey PM
    Crit Rev Microbiol; 2009; 35(2):81-108. PubMed ID: 19514910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the longevity of the beta-lactam antibiotics and of antibiotic/beta-lactamase inhibitor combinations.
    Buynak JD
    Biochem Pharmacol; 2006 Mar; 71(7):930-40. PubMed ID: 16359643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of the growth of six potentially-pathogenic mycobacteria by beta-lactam/beta-lactamase-inhibitors.
    Prabhakaran K; Harris EB; Randhawa B
    Microbios; 1997; 91(366):7-14. PubMed ID: 9467917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains.
    Brauers J; Frank U; Kresken M; Rodloff AC; Seifert H
    Clin Microbiol Infect; 2005 Jan; 11(1):24-30. PubMed ID: 15649300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Re-evaluation of the gastrointestinal effects of beta-lactam inhibitors of beta-lactamase].
    Sábada B
    Rev Esp Quimioter; 1998 Dec; 11(4):377-9. PubMed ID: 10336322
    [No Abstract]   [Full Text] [Related]  

  • 7. New β-lactam antibiotics and β-lactamase inhibitors.
    Bush K; Macielag MJ
    Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Beta-lactam/beta-lactamase inhibitor combinations for oral administration].
    Franciolli M
    Schweiz Med Wochenschr; 1991 Sep; 121(39):1399-407. PubMed ID: 1925470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.
    Dinçer I; Ergin A; Kocagöz T
    Int J Antimicrob Agents; 2004 Apr; 23(4):408-11. PubMed ID: 15081094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase.
    Li C; Nicolau DP; Lister PD; Quintiliani R; Nightingale CH
    J Antimicrob Chemother; 2004 Feb; 53(2):297-304. PubMed ID: 14729755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of metallo-beta-lactamase generated from beta-lactam antibiotics.
    Badarau A; Llinás A; Laws AP; Damblon C; Page MI
    Biochemistry; 2005 Jun; 44(24):8578-89. PubMed ID: 15952764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic and clinical aspects of beta-lactam antibiotics and beta-lactamases.
    Kotra LP; Mobashery S
    Arch Immunol Ther Exp (Warsz); 1999; 47(4):211-6. PubMed ID: 10483868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evolution of resistance to beta-lactam inhibitors of beta-lactamases].
    Alóz JI
    Rev Esp Quimioter; 1998 Dec; 11(4):375-6. PubMed ID: 10336321
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic properties of beta-lactamase inhibitors.
    de la Pena A; Derendorf H
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):63-75. PubMed ID: 10082170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Characterization of the resistance to combinations of beta lactams and inhibitors of beta-lactamases in Escherichia coli. Effect of the type and amount of beta-lactamase production].
    del Mar Pérez-Moreno M; Pous-Miralles G; Romera-Sastre G; Panisello-Bertomeu JM; Jardí-Baiges AM; Zarazoga-López J
    Enferm Infecc Microbiol Clin; 1997 Nov; 15(9):477-81. PubMed ID: 9527373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanisms of resistance to beta-lactam inhibitors of beta-lactamases].
    Blázquez J
    Rev Esp Quimioter; 1998 Dec; 11(4):368-9. PubMed ID: 10336318
    [No Abstract]   [Full Text] [Related]  

  • 17. [Problems in the detection of resistance to beta-lactam inhibitors of beta-lactamases in the laboratory].
    Castillo García FJ
    Rev Esp Quimioter; 1998 Dec; 11(4):372-4. PubMed ID: 10336320
    [No Abstract]   [Full Text] [Related]  

  • 18. [Beta-lactam inhibitors of beta-lactamases in Mycobacterium].
    Galán JC
    Rev Esp Quimioter; 1998 Dec; 11(4):386-8. PubMed ID: 10336326
    [No Abstract]   [Full Text] [Related]  

  • 19. Structure-based design of beta-lactamase inhibitors. 2. Synthesis and evaluation of bridged sulfactams and oxamazins.
    Hubschwerlen C; Angehrn P; Gubernator K; Page MG; Specklin JL
    J Med Chem; 1998 Oct; 41(21):3972-5. PubMed ID: 9767634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered Amp C β-lactamase as a fluorescent screening tool for class C β-lactamase inhibitors.
    Tsang MW; Chan PH; So PK; Ma DL; Tsang CW; Wong KY; Leung YC
    Anal Chem; 2011 Mar; 83(6):1996-2004. PubMed ID: 21338058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.